Toxicity of novel nanosized formulations used in medicine

Methods in Molecular Biology

Volumn 1028, Issue , 2013, Pages 47-74

  El Ansary, Afaf ^a   Al Daihan, Sooad ^a   Bacha, Abir Ben ^a   Kotb, Malak ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Nanocapsules; Nanomedicine; Nanoparticles; Nanoshells; Nanoshuttles; Nanotoxicity; Quantum dots

Indexed keywords

CALCIUM FLUORIDE; CARBON NANOTUBE; ECHOGENIC BUBBLE; MAGNETIC NANOPARTICLE; MULTI WALLED NANOTUBE; NANOCAPSULE; NANOMATERIAL; NANOSHELL; NANOSHUTTLE; QUANTUM DOT; UNCLASSIFIED DRUG;

CELL MEMBRANE; DRUG TOXICITY; HUMAN; MITOCHONDRION; NANOMEDICINE; NANOTECHNOLOGY; NANOTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84883242816     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-475-3_4     Document Type: Review

References (128)

1. Shvedova AA, Kisin ER, Porter D, Schulte P, Kagan VE, Fadeel B et al (2009) Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus? Pharmacol Ther 121:192-204
2. Zhang S, Bian Z, Gu C, Zhang Y, He S, Gu N et al (2007) Preparation of anti-human cardiac troponin I immunomagnetic nanoparticles and biological activity assays. Colloids Surf B Biointerfaces 55:143-148
3. Oberdörster G, Oberdörster E, Oberdörster J (2005) Nanotoxicology: An emerging discipline evolving from studies of ultrafi ne particles. Environ Health Perspect 113: 823-839
4. Oberdörster G, Stone V, Donaldson K (2007) Toxicology of nanoparticles: A historical perspective. Nanotoxicology 1:2-25
5. Dreher KL (2004) Health and environmental impact of nanotechnology: Toxicological assessment of manufactured nanoparticles. Toxicol Sci 77:3-5
6. Allen TM, Cullis PM (2004) Drug delivery systems: Entering the main stream. Science 303:1818-1822
7. Oberdörster G (2000) Toxicology of ultrafi ne particles; in vivo studies. Phil Trans R Soc Lond A 358:2719-2740
8. Borm PJA, Schins RPF, Albrecht A (2004) Inhaled particles and lung cancer, part B: Paradigms and risk assessment. Int J Cancer 110:3-14
9. Chalupa DC, Morrow PE, Oberdörster G, Utell MJ, Frampton MW (2004) Ultrafi ne particle deposition in subjects with asthma. Environ Health Perspect 112:679-682
10. Johanston CJ, Finkelstein N, Gelein R, Bagos R, Oberdörster G (1996) Characterization of the early pulmonary infl ammatory response associated with PTFE fume exposure. Toxicol Appl Pharmacol 140:154-163
11. Donaldson K, Brown D, Clouter A, Duffin R, MacNee W, Renwick L et al (2002) The pulmonary toxicology of ultrafi ne particles. J Aerosol Med 15:213-220
12. Boswell C (2002) Nanocrystalline materials for personal care. Chemical Market Reporter November 11:6
13. Dunford R, Salinaro A, Cai L, Serpone N, Horikoshi S, Hidaka H et al (1997) Chemical oxidation and DNA damage catalysed by inorganic sunscreen ingredients. FEBS Lett 418:87-90
14. Hidaka H, Horikoshi S, Serpone N, Knowland J (1997) In vitro photochemical damage to DNA, RNA and bases by an inorganic sunscreen agent on exposure to UVA and UVB radiation. J Photochem Photobiol 111:203-213
15. Li X, Quan X, Kutal C (2004) Synthesis and photocatalytic properties of quantum confi ned titanium dioxide nanoparticle. Scr Mater 50:499-505
16. 2 particles at the high energy ion nanoprobe LIPSION. Nucl Inst Meth Phys Res B Beam Interact Mater Atoms 219-220: 82-86
17. Powell JJ, Harvey RSJ, Ashwood P, Wolstencroft R, Gershwin ME, Thompson RPH (2000) Immune potentiation of ultrafi ne dietary particles in normal subjects and patients with infl ammatory bowel disease. J Autoimmun 14:99-105
18. Hugot J (2004) Infl ammatory bowel disease: A complex group of genetic disorders. Best Pract Res Clin Gastroenterol 18:451-462
19. Urban RM, Jacobs JJ, Tomlinson MJ, Gavrilovic J, Black J, Peoch M (2000) Dissemination of wear particles to the liver, spleen and abdominal lymph nodes of patients with hip and knee replacement. J Bone Joint Surg Am 82A:457-477
20. Gatti AM, Rivasi F (2002) Biocompatibility of micro-And nanoparticles. Part I: In liver and kidney. Biomaterials 23:2381-2387
21. Gatti AM (2004) Biocompatibility of micro and nano-particles in the colon. Part II. Biomaterials 25:385-392
22. Szebeni J, Baranyi L, Savay S, Milisevits J, Bunger R, Laverman P et al (2002) Role of complement activation in hypersensitivity reactions to Doxil and HYNIC PEG liposomes: Experimental and clinical studies. J Liposome Res 12:165-172
23. Derfus AM, Chan WCW, Bhatia SN (2004) Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 4:11-18
24. Webster TJ (2006) Nanomedicine-what's in a defi nition. Int J Nanomedicine 1:115-116
25. Chen H, Langer R (1998) Oral particulate delivery: Status and future trends. Adv Drug Deliv Rev 34:339-350
26. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329-347
27. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B et al (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specifi c mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20:409-416
28. Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R et al (2005) Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotech 1:235-258
29. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer. Nat Nanotechnol 2:751-760
30. Alivisatos AP (2002) Less is more in medicine. In: Understanding nanotechnology, Warner Book, New York, NY, pp 56-69
31. Ratner M, Ratner D (2003) Nanotechnology: A gentle introduction to the next big idea. Prentice-Hall, Upper Saddle River, NJ
32. Kipen HM, Laskin DL (2005) Smaller is not always better: Nanotechnology yields nanotoxicology. Am J Physiol 289:L696-L697
33. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJAM (2007) What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 49:217-229
34. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: Current status and future prospects. FASEB J 19:311-330
35. Garnett MC, Kallinteri P (2006) Nanomedicines and nanotoxicology: Some physiological principles, Occup Med 56:307-311
36. Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies NM (2008) Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 60:929-938
37. Wiesenthal A, Hunter L, Wang S, Wickliffe J, Wilkerson M (2011) Nanoparticles: Small and mighty. Int J Dermatol 5:247-254
38. Hardman R (2006) A toxicological review of quantum dots: Toxicity depends on physicochemical and environmental factors. Environ Health Perspect 114:165-172
39. Denison RA (2005) Environmental and safety impacts on nanotechnology: What research is needed? http://www.environmentaldefense. o r g / d o c u m e n t s / 5 1 3 6 - D e n i s o n HousetestimonyOnNano.pdf
40. Liang HD, Blomley MJK (2003) The role of ultrasound in molecular imaging. Br J Radiol 76:S140-S150
41. Stern JM, Cadeddu JA (2008) Emerging use of nanoparticles for the therapeutic ablation of urologic malignancies. Urol Oncol 26: 93-96
42. Müller RH, Keck CM (2004) Drug delivery to the brain-realization by novel drug carriers. J Nanosci Nanotechnol 4:471-483
43. Moghimi SM, Hunter AC, Murray J (2001) Long-circulating and target-specifi c nanoparticles: Theory to practice. Pharmacol Rev 53:283-318
44. Ito A, Shinkai M, Honda H, Kobayashi T (2005) Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 100: 1-11
45. Pankhurst QA, Connolly J, Jones SK, Dobson J (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D 36: R167-R181
46. Vasir JK, Labhasetwar V (2005) Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 4:363-374
47. Moroz P, Jones SK, Gray BN (2002) Magnetically mediated hyperthermia: Current status and future directions. Int J Hyperthermia 18:267-284
48. Sun L, Chow LC (2008) Preparation and properties of nano-sized calcium fluoride for dental applications. Dent Mater 24:111-116
49. Saad M, Garbuzenko OB, Ber E, Chandna P, Khandare JJ, Pozharov VP et al (2008) Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most effi-cient for tumor-specifi c treatment and imaging? J Control Release 130:107-114
50. Ferrara K, Pollard R, Borden M (2007) Ultrasound microbubble contrast agents: Fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng 9: 415-447
51. Bull JL (2007) The application of microbubbles for targeted drug delivery. Expert Opin Drug Deliv 4:475-493
52. Chen S, Shohet RV, Bekeredjian R, Frenkel P, Grayburn PA (2003) Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid deoxyribonucleic acid by ultrasound-Targeted microbubble destruction. J Am Coll Cardiol 42:301-308
53. Lum AF, Borden MA, Dayton PA, Kruse DE, Simon SI, Ferrara KW (2006) Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J Control Release 111:128-134
54. Souza GR, Christianson DR, Staquicini FI, Ozawa MG, Snyder EY, Sidman RL et al (2006) Networks of gold nanoparticles and bacteriophage as biological sensors and celltargeting agents. Proc Natl Acad Sci USA 103:1215-1220
55. Souza GR, Staquicini FI, Christianson DR, Ozawa MG, Miller JH, Pasqualini R et al (2010) Combinatorial targeting and nanotechnology applications. Biomed Microdevices 12:597-606
56. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T et al (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale deliverysystem. Nature 436: 568-572
57. Garcia-Bennett A, Nees M, Fadeel B (2011) In search of the holy grail: Folate-Targeted nanoparticles for cancer therapy. Biochem Pharmacol 181:976-984
58. Naqvi S, Samim M, Abdin M, Ahmed FJ, Maitra A, Prashant C et al (2010) Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine 16:983-989
59. Behlke MA (2006) Progress towards in vivo use of siRNAs. Mol Ther 13:644-670
60. Xie FY, Woodle MC, Lu PY (2006) Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 11:67-73
61. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J (2007) Interfering with disease: A progress report on siRNAbased therapeutics. Nat Rev Drug Discov 6:443-453
62. Pouton CW, Seymour LW (2001) Key issues in non-viral gene delivery. Adv Drug Deliv Rev 46:187-203
63. Elouahabi A, Ruysschaert JM (2005) Formation and intracellular traffi cking of lipoplexes and polyplexes. Mol Ther 11:336-347
64. Torchilin VP (2000) Drug targeting. Eur J Pharm Sci 11:S81-S91
65. Nighswonger G (1999) A Medical Device Link MD& DI column: New polymers and nanotubes add muscle to prothetic limbs, http://www.devicelink.com/ mddi/ archive/99/08/004.html
66. Oberdörster G (2006) Toxicology of airborn environment and occupational particles. http://www2.envmed.rochester.edu/ envmed/tox/faculty/ oberdoerster.html
67. Lam CW, James JT, McCluskey R, Hunter RL (2004) Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intractracheal instillation. Toxicol Sci 77: 126-134
68. Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR (2004) Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci 77:117-125
69. Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WAH, Seaton A et al (2008) Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 3:423-428
70. Chou CC, Hsiao HY, Hong QS, Chen CH, Peng YW, Chen HW et al (2008) Singlewalled carbon nanotubes can induce pulmonary injury in mouse model. Nano Lett 3: 437-445
71. Mitchell LA, Gao J, Vander WR, Gigliotti A, Burchiel SW, McDonald JD (2007) Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes. Toxicol Sci 100:203-214
72. Muller J, Huaux F, Moreau N, Misson P, Heilier JF, Delos M et al (2005) Respiratory toxicity of multi-wall carbon nanotubes. Toxicol Appl Pharmacol 207:221-231
73. Di Giorgio ML, Di Bucchianico S, Ragnelli AM, Aimola P, Santucci S, Poma A (2011) Effects of single and multi walled carbon nanotubes on macrophages: Cyto and genotoxicity and electron microscopy. Mutat Res 722:20-31
74. Donaldson K, Stone V, Tran CL, Kreyling W, Borm PJA (2004) Nanotoxicology. Occup Environ Med 61:727-728
75. Limbach LK, Wick P, Manser P, Grass RN, Bruinink A, Stark WJ (2007) Exposure of engineered nanoparticles to human lung epithelial cells: Infl uence of chemical composition and catalytic activity on oxidative stress. Environ Sci Technol 41:4158-4163
76. Wright JB, Lam K, Buret AG, Olson ME, Burrell RE (2002) Early healing events in a porcine model of contaminated wounds: Effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen 10:141-151
77. Supp AP, Neely AN, Supp DM, Warden GD, Boyce ST (2005) Evaluation of cytotoxicity and antimicrobial activity of Acticoat burn dressing for management of microbial contamination in cultured skin substitutes grafted to athymic mice. J Burn Care Rehabil 26: 238-246
78. Chen HW, Su SF, Chien CT, Lin WH, Yu SL, Chou CC et al (2006) Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J 20:2393-2395
79. Muangman P, Chuntrasakul C, Silthram S, Suvanchote S, Benjathanung R, Kittidacha S et al (2006) Comparison of effi cacy of 1% silver sulfadiazine and Acticoat™ for treatment of partial-Thickness burn wounds. J Med Assoc Thai 89:953-958
80. Paddle-Ledinek JE, Nasa Z, Cleland HJ (2006) Effect of different wound dressings on cell viability and proliferation. Plast Reconstr Surg 117:110S-118S
81. Braydich-Stolle L, Hussain S, Schlager JJ, Hofmann MC (2005) In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol Sci 88:412-419
82. Ahamed M, AlSalhi MSM, Siddiqui KJ (2010) Silver nanoparticle applications and human health. Clin Chim Acta 411:1841-1848
83. Ahamed M, Karns M, Goodson M, Rowe J, Hussain SM, Schlager JJ et al (2008) DNA damage response to different surface chemistry of silver nanoparticles in mammalian cells. Toxicol Appl Pharmacol 233:404-410
84. 25:664-670
85. Hackenberg S, Scherzed A, Kessler M, Hummel S, Technau A, Froelich K et al (2011) Silver nanoparticles: Evaluation of DNA damage, toxicity and functional impairment in human mesenchymal stem cell. Toxicol Lett 201:27-33
86. El Badawy AM, Silva RG, Morris B, Scheckel KG, Suidan MT, Tolaymat TM (2011) Surface charge-dependent toxicity of silver nanoparticles. Environ Sci Technol 45: 283-287
87. Takenaka S, Karg E, Roth C, Schulz H, Ziesenis A, Heinzmann U et al (2001) Pulmonary and systemic distribution of inhaled ultrafi ne silver particles in rats. Environ Health Perspect 109:547-551
88. Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ (2005) In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol in Vitro 19:975-983
89. Hussain SM, Javorina AK, Schrand AM, Duhart HM, Ali SF, Schlager JJ (2006) The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci 92:456-463
90. Mirsattari SM, Hammond RR, Sharpe MD, Leung FY, Young GB (2004) Myoclonic status epilepticus following repeated oral ingestion of colloidal silver. Neurology 62: 1408-1410
91. Chung YC, Chen IH, Chen CJ (2008) The surface modifi cation of silver nanoparticles by phosphoryl disulfi des for improved biocompatibility and intracellular uptake. Biomaterials 29:1807-1816
92. Pujalte I, Passagne I, Brouillaud B, Treguer M, Durand E, Ohayon-Courtes C et al (2011) Cytotoxicity and oxidative Stress induced by different metallic nanoparticles on human kidney cells. Part Fibre Toxicol 8:10
93. Zhao Y, Meng H, Chen Z, Zhao F, Chai ZF (2007) Dependence of nanotoxicity on nanoscale characteristics and strategies for reducing and eliminating nanotoxicity. In: Zhao YL, Nalwa HS (eds) Nanotoxicology. American Scientifi c, Stevenson Ranch, CA, pp 265-280
94. Galla JH (2000) Metabolic alkalosis. J Am Soc Nephrol 11:369-375
95. Williams AJ (1998) ABC of oxygen. Assessing and interpreting arterial blood gases and acid-base balance. Br Med J 317:1213-1216
96. Tao TY, Liu F, Klomp L, Wijmenga C, Gitlin JD (2003) The copper toxicosis gene product Murr 1 directly interacts with the Wilson disease protein. J Biol Chem 278:41593-41596
97. Meng H, Chen Z, Xing G, Yuan H, Chen C, Zhao F et al (2007) Ultrahigh reactivity provokes nanotoxicity: Explanation of oral toxicity of nano-copper particles. Toxicol Lett 175:102-110
98. Li L, Zhu YJ (2006) High chemical reactivity of silver nanoparticles toward hydrochloric acid. J Colloid Interface Sci 303:415-418
99. Driscoll KE, Lindenschmidt RC, Maurer JK, Higgins JM, Ridder G (1990) Pulmonary response to silica or titanium dioxide: Infl ammatory cells, alveolar macrophage-derived cytokines, and histopathology. Am J Respir Cell Mol Biol 2:381-390
100. Ferin J, Oberdorster G (1985) Biological effects and toxicity assessment of titanium dioxides: Anatase and rutile. Am Ind Hyg Assoc J 46:69-72
101. Bermudez E, Mangum JB, Asgharian B, Wong BA, Reverdy EE, Janszen DB et al (2002) Long-Term pulmonary responses of three laboratory rodent species to subchronic inhalation of pigmentary titanium dioxide particles. Toxicol Sci 70:86-97
102. Bermudez E, Mangum JB, Wong BA, Asgharian B, Hext PM, Warheit DB et al (2004) Pulmonary responses of mice, rats, and hamsters to subchronic inhalation of ultrafi ne titanium dioxide particles. Toxicol Sci 77:347-357
103. 2 particles containing various commercial coatings. Toxicologist 72:298A
104. 2 particles: Differential responses related to surface properties. Toxicology 230:90-104
105. 2 primary particles in mice. Environ Toxicol Pharmacol 24:239-244
106. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MNVR (2006) Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Release 113: 189-207
107. Ankola DD, Viswanand B, Bhardwaj V, Ramarao P, Kumar MNVR (2007) Development of potent oral nanoparticulate formulation of coenzyme Q 10 for treatment of hypertension: Can the simple nutritional supplements be used as fi rst line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm 67:361-369
108. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR (2009) Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcuminn administered with piperine as absorption enhancer. Eur J Pharm Sci 37:223-230
109. Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Kumar MNVR (2006) Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxix system for oral administration. J Drug Target 14:27-34
110. Bala I, Bhardwaj V, Hariharan S, Sitterberg S, Bakowsky U, Kumar MNVR (2005) Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 16:2819-2822
111. Sonaje K, Italia JL, Sharma G, Bhardwaj V, Tikoo K, Kumar MNVR (2007) Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant effi cacy against cyclosporine a-induced nehrotoxicity in rats. Pharm Res 24:899-908
112. Italia JL, Datta P, Ankola DD, Kumar MNVR (2008) Nanoparticles enhance per oral bioavailability of poorly available molecules: Epigallocatechin gallate nanoparticles ameliorates cyclosporine induced nephrotoxicity in rats at three times lower dose than oral solution. J Biomed Nanotechnol 4:304-312
113. Chomouckaa J, Drbohlavovaa J, Babulab P, Adamc V, Hubaleka J, Provaznikd I et al (2010) Cell toxicity and preparation of streptavidin-modifi ed iron nanoparticles and glutathione-modifi ed cadmium-based quantum dots. Procedia Eng 5:922-925
114. Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q et al (2011) Targeting the brain with PEGPLGA nanoparticles modifi ed with phagedisplayed peptides. Biomaterials 32: 4943-4950
115. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA (2007) The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci 134-135:167-174
116. Cedervall T, Lynch I, Foy M, Berggård T, Donnelly SC, Cagney G et al (2007) Detailed identifi cation of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed 46:5754-5756
117. Lynch I, Dawson KA (2008) Proteinnanoparticle interactions. Nanotoday 3:40-47
118. Borm PJA, Kreyling W (2004) Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J Nanosci Nanotechnol 4:521-531
119. Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaële D et al (2007) Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: Role of apolipoproteins on receptor-mediated endocytosis. Biomacromolecules 8:793-799
120. Dutta D, Sundaram SK, Teeguarden JG, Riley BJ, Fifield LS, Jacobs JM et al (2007) Adsorbed proteins infl uence the biological activity and molecular targeting of nanomaterials. Toxicol Sci 100:303-315
121. Shen XC, Liou XY, Ye LP, Liang H, Wang ZY (2007) Spectroscopic studies on the interaction between human hemoglobin and CdS quantum dots. J Colloid Interface Sci 311:400-406
122. Mu Q, Li Z, Li X, Mishra SR, Zhang B et al (2009) Characterization of protein clusters of diverse magnetic nanoparticles and their dynamic interactions with human cells. J Phys Chem C 113:5390-5395
123. Karmali PP, Simberg D (2011) Interactions of nanoparticles with plasma proteins. Implications on clearance and toxicity of drug delivery system. Expert Opin Drug Deliv 8:343-357
124. Goppert TM, Muller RH (2005) Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 302:172-186
125. Gessner A, Lieske A, Paulke BR, Müller RH (2003) Functional groups on polystyrene model nanoparticles: Infl uence on protein adsorption. J Biomed Mater Res 65:319-326
126. Kurath M, Maasen S (2006) Toxicology as a nanoscience?-disciplinary identities reconsidered. Part Fibre Toxicol 3:1-13
127. Kabanov AV (2006) Polymer genomics: An insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev 58: 1597-1621
128. Miller J (2003) Beyond biotechnology: FDA regulations of nanomedicine. Columbia Sci Technol Law Rev 4:E5